<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00094341</url>
  </required_header>
  <id_info>
    <org_study_id>20040201</org_study_id>
    <nct_id>NCT00094341</nct_id>
  </id_info>
  <brief_title>Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes</brief_title>
  <official_title>An Open-Label, Randomized, Crossover Study to Assess Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the preference of RA patients for the new Enbrel®
      (etanercept) pre-filled syringe in patients who are already taking Enbrel®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients preferring the etanercept auto-injector to the etanercept pre-filled syringe.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients preferring the etanercept auto-injector to the etanercept pre-filled syringe as well as to the lyophilized preparation in the following categories:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of use</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand discomfort during the injection</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with number of steps</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time involved with the injection</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nervousness with injection</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confidence with the injection</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Convenience of use and</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall preference with the auto-injector or pre-filled syringes compared to the lyophilized preparation.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the ability of patients to properly use by themselves either device independently and identify any sections of the instructions that were not clear, that may have led to loss of sterility to incomplete dosing</measure>
  </secondary_outcome>
  <enrollment>215</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have established RA diagnosis as determined by ACR criteria

          -  Be current user of etanercept-lyophilized preparation for at least 4 consecutive weeks
             of etanercept dosing on either a once weekly or twice weekly regimen

          -  Subject must be able to self inject

          -  Give written informed consent

        Exclusion Criteria:

          -  Subject is currently enrolled in or has not yet completed at least 30 days since
             ending other investigational device or drug trial(s), or subject is receiving other
             investigational agent(s)

          -  Subject of childbearing potential is pregnant (e.g., positive HCG test) or is
             breast-feeding

          -  Elective surgery is planned during study period

          -  Subjects allergic to latex
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.enbrel.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2004</study_first_submitted>
  <study_first_submitted_qc>October 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2004</study_first_posted>
  <last_update_submitted>December 4, 2008</last_update_submitted>
  <last_update_submitted_qc>December 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Arthritis</keyword>
  <keyword>Rheumatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

